Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 239 posts found.

hcv_credit_bruceblaus

New hepatitis C combo boasts 97% cure rate for just $300

April 12, 2018
Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …

News
john_mchutchison

New Chief Science and Medical Officers for Gilead

March 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment

Gilead has announced that Dr Norbert Bischofberger, its Chief Scientific Officer (CSO), Executive Vice President of Research and Development and …

Appointment
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …

News
gilead_hq_at_stockley_park_london

Switching to Gilead’s Biktarvy proves non-inferior in HIV patients

March 6, 2018
Manufacturing and Production, Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …

News
gilead-sciences

Gilead investigational data gives hope for HIV eradication in humans

March 5, 2018
Research and Development, Sales and Marketing Gilead, HIV, pharma

Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620, its investigational …

News
gilead-sciences

Gilead seals $3bn deal, hoping for off-the-shelf CAR-T

February 23, 2018
Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …

News
gavel

Long-running, $2.5bn lawsuit swings in Gilead’s favour

February 19, 2018
Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi

The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …

News
gilead-sciences

FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

February 8, 2018
Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

News
gilead-sciences

Gilead aims to claim edge with Pfizer CAR-T combo

January 18, 2018
Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical

Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …

News
truvada-web

AIDS charity lambasts “ethically challenged” Gilead over price hikes

January 11, 2018
Sales and Marketing AIDS, Gilead, HIV, Truvada, biotech, drugs, pharma, pharmaceutical

The AIDS Healthcare Foundation (AHF) has strongly criticised Gilead prices increases across the board for its HIV and AIDS treatment, …

News
gilead-sciences

Gilead makes $567m strategic acquisition for next-gen CAR-T

December 8, 2017
Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical

It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …

News
gilead-sciences

Gilead launches hep C drug Sovaldi in China at one-fifth of US price

November 29, 2017
Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi

Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …

News
640px-hiv-budding-color

Learning lessons from HIV to change the treatment access landscape

November 23, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, HIV, pharma

Greg Alton, Executive Vice President of Corporate and Medical Affairs at Gilead, reveals how the rapid development and distribution of …

Feature
gsk_boronia_australia

FDA approves first-ever two-drug HIV regimen, GSK’s Juluca

November 22, 2017
Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma

GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …

News
novartis_hq_day

Novartis aims for CAR-T double-approval in Europe

November 6, 2017
Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

News

Latest content

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024

Nona Biosciences announced agreement with AstraZeneca for tumour targeted therapies

May 24, 2024

BioGen to acquire Human Immunology Biosciences for $1.15bn

May 23, 2024

Merck to acquire Mirus Bio for $600m

May 23, 2024

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024